Alchemab Therapeutics, a London-based biopharma company developing neurogenerative disease treatments, landed a $415 million licensing agreement with Eli Lilly.
Why it matters: It follows a string of biotech licensing deals, which are becoming an increasingly lucrative option for growth-stage drug developers.
/2025/05/06/1746548098014.gif?w=3840)
